Esbriet is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF).
IPF is different from other interstitial lung diseases (ILD), or diseases that cause inflammation and scarring of the lungs. Esbriet is specifically studied and approved for use in IPF, which is a certain type of ILD.
It is not known if Esbriet is safe and effective in children.
No, Esbriet is not approved to treat other ILDs. Esbriet is specifically studied and approved for use in IPF, which is a certain type of ILD. IPF is different from other ILDs, or diseases that cause inflammation and scarring of the lungs.
Although lung function that is lost cannot be restored, treatment may help maintain more of your lung function by slowing the progression of the disease. This treatment may also cause side effects.
Learn more about the side effects >
In a 1-year clinical study, people who took Esbriet had better breathing capacity compared with those who did not take Esbriet (193 mL difference in forced vital capacity [FVC]). Patients taking Esbriet had an average decline of 235 mL in FVC compared with a 428 mL decline for patients who did not take Esbriet.
One 72-week study showed similar results. Another 72-week study did not show a significant difference between people who took Esbriet and those who did not.
Learn more about the results of the Esbriet studies >
At the end of a 1-year clinical study of people with IPF, more than twice as many people who took Esbriet preserved baseline lung function compared to those who did not take Esbriet.
Talk to your doctor about IPF treatment with Esbriet and if it may be right for you.
There may be options to help you afford your Genentech medicine, no matter what type of health insurance you have.
Esbriet Access Solutions can:
Some people may have serious side effects when taking Esbriet, including liver problems, sensitivity to sunlight (including sunlamps), severe skin reactions or stomach problems.
Other reported side effects that occurred in 10% or more of people treated with Esbriet in clinical studies included:
These are not all of the side effects reported with Esbriet. For more information, ask your doctor or pharmacist. See Managing Side Effects to learn more about possible side effects of Esbriet.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or to Genentech at 1-888-835-2555.
In the clinical studies of Esbriet, some side effects occurred soon after starting treatment and/or decreased over time:
These are not the only side effects. Be sure to talk to your healthcare provider immediately if you experience any side effects.
See How to Take Esbriet to learn about the dosing schedule and starting treatment.
Esbriet dosing is intended to allow your body to gradually adjust to the medicine.
You should always take Esbriet with food. Doing so may help reduce certain side effects, including dizziness or nausea. Taking Esbriet with food decreases how quickly Esbriet is absorbed. It also decreases the drug level of Esbriet in the blood.
IPF is progressive, and once damage occurs, it cannot be undone. It is also unpredictable: there is no way to know when your IPF will begin to get worse. Since IPF is progressive, irreversible, and unpredictable, it is important to talk to your doctor about IPF treatment today. There is no way to undo the damage caused by IPF. However, Esbriet may help preserve more lung function by slowing disease progression. Talk to your doctor about Esbriet.
Esbriet may cause serious side effects, including liver problems, sun sensitivity, severe skin reactions and stomach problems. Use the tips below to help manage and prevent certain side effects, or
Read more about managing side effects >
Preventing sun sensitivity
Managing nausea and dizziness
Learn more about how to take Esbriet >
Tell your doctor immediately if you have any side effects while you are taking Esbriet. He or she may need to reduce your dose of Esbriet or ask you to stop taking it for a short time to help manage side effects.
It is important to do everything you can to preserve more lung function by slowing disease progression because there is no way to restore lost lung function.
Learn more about why lung function matters >
Starting and staying on Esbriet treatment as prescribed by your doctor can be an important way to help preserve more of the lung function you have today.
Only you and your doctor can decide if Esbriet is right for you. If you have been diagnosed with IPF, talk to your doctor about starting Esbriet.
You can schedule up to 5 free and optional one-on-one educational sessions with a Clinical Education Manager (CEM) specially trained in IPF and Esbriet to learn more about your condition and treatment.
CEMs offer education related to IPF and Esbriet, managing possible side effects, and support options that may be available to you.
Call 1-844-My-Esbriet (1-844-693-7274) and press 4 to schedule a session.
Clinical Education Managers are Genentech employees who educate about IPF and Esbriet. They do not provide medical advice to patients. If you have questions about your health or treatment, you are encouraged to contact your healthcare provider.
The FDA approved Esbriet for the treatment of IPF in October 2014.
The best source for information regarding clinical trials is your pulmonologist. They may be able to direct you to study centers. You can also call Genentech's Clinical Trial Information Support Line at (888) 662-6728 to understand what studies Genentech has ongoing. You can look up clinical trials on PulmonaryFibrosisFoundation.org or clinicaltrials.gov.
After you and your doctor decide you should move to the brown tablets, your doctor will write a new prescription. Expect and answer phone calls:
Remember: Talk to your specialty pharmacy about when to fill your new prescription.
Yes. Talk with your doctor if you would like to change your Esbriet prescription.
Take Esbriet as your doctor prescribes. There are no studies showing how effective Esbriet is if someone chews or crushes it.
More than 50,000 patients have taken Esbriet.
Find out if you qualify for additional resources to help pay for your Esbriet treatment.
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.